• João Vian, Círia Pereira, Victor Chavarria, Cristiano Köhler, Brendon Stubbs, João Quevedo, Sung-Wan Kim, André F Carvalho, Michael Berk, and Brisa S Fernandes.
• Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
• Bmc Med. 2017 Aug 1; 15 (1): 144.

AbstractDepression remains a debilitating condition with an uncertain aetiology. Recently, attention has been given to the renin-angiotensin system. In the central nervous system, angiotensin II may be important in multiple pathways related to neurodevelopment and regulation of the stress response. Studies of drugs targeting the renin-angiotensin system have yielded promising results. Here, we review the potential beneficial effects of angiotensin blockers in depression and their mechanisms of action. Drugs blocking the angiotensin system have efficacy in several animal models of depression. While no randomised clinical trials were found, case reports and observational studies showed that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers had positive effects on depression, whereas other antihypertensive agents did not. Drugs targeting the renin-angiotensin system act on inflammatory pathways implicated in depression. Both preclinical and clinical data suggest that these drugs possess antidepressant properties. In light of these results, angiotensin system-blocking agents offer new horizons in mood disorder treatment.

22 keywords...

hide…